IL278466B1 - Anti-dll3 antibodies and uses thereof - Google Patents

Anti-dll3 antibodies and uses thereof

Info

Publication number
IL278466B1
IL278466B1 IL278466A IL27846620A IL278466B1 IL 278466 B1 IL278466 B1 IL 278466B1 IL 278466 A IL278466 A IL 278466A IL 27846620 A IL27846620 A IL 27846620A IL 278466 B1 IL278466 B1 IL 278466B1
Authority
IL
Israel
Prior art keywords
dll3 antibodies
dll3
antibodies
Prior art date
Application number
IL278466A
Other languages
English (en)
Hebrew (he)
Other versions
IL278466A (https=
Original Assignee
Phanes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc
Publication of IL278466A publication Critical patent/IL278466A/en
Publication of IL278466B1 publication Critical patent/IL278466B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL278466A 2018-05-08 2020-11-03 Anti-dll3 antibodies and uses thereof IL278466B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862668427P 2018-05-08 2018-05-08
US201862754207P 2018-11-01 2018-11-01
US201962787815P 2019-01-03 2019-01-03
PCT/US2019/029888 WO2019217145A1 (en) 2018-05-08 2019-04-30 Anti-dll3 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
IL278466A IL278466A (https=) 2021-03-01
IL278466B1 true IL278466B1 (en) 2026-04-01

Family

ID=68467536

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278466A IL278466B1 (en) 2018-05-08 2020-11-03 Anti-dll3 antibodies and uses thereof

Country Status (13)

Country Link
US (3) US12037391B2 (https=)
EP (1) EP3790586A4 (https=)
JP (1) JP7455388B2 (https=)
KR (1) KR102922314B1 (https=)
CN (2) CN112584860B (https=)
AU (1) AU2019267349B2 (https=)
BR (1) BR112020021280A2 (https=)
CA (1) CA3097193A1 (https=)
IL (1) IL278466B1 (https=)
MX (1) MX2020011914A (https=)
SG (1) SG11202009772PA (https=)
WO (1) WO2019217145A1 (https=)
ZA (1) ZA202006318B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3132202A1 (en) * 2019-04-08 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
CA3160436A1 (en) * 2019-12-17 2021-06-24 Jack Chongyang LI Bispecific antibodies with alternatively matched interchain cysteines and uses thereof
AU2022217274A1 (en) * 2021-02-05 2023-07-27 Phanes Therapeutics, Inc. Bispecific antibodies with charge pairs and uses thereof
CN117529337A (zh) * 2021-05-08 2024-02-06 上海齐鲁制药研究中心有限公司 针对dll3的结合分子及其应用
CN116271079B (zh) * 2021-07-30 2025-11-14 上海复旦张江生物医药股份有限公司 一种抗dll3抗体及其制备方法、其药物偶联物和应用
KR20240040090A (ko) * 2021-07-30 2024-03-27 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 항-dll3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도
MX2024003331A (es) * 2021-09-17 2024-06-19 Wuxi Biologics Ireland Ltd Moleculas de union a d3 y usos de estas.
TW202346346A (zh) * 2021-12-23 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途
CN114292334B (zh) * 2021-12-24 2023-11-17 杭州贤至生物科技有限公司 抗可替宁特异性抗体、质粒载体及方法
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
CN116789836B (zh) * 2023-08-14 2024-01-05 浙江时迈药业有限公司 针对dll3的抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150003169A (ko) * 2012-02-24 2015-01-08 스템 센트알엑스 인코포레이티드 Ｄｌｌ3 조절물질들 및 사용 방법
WO2017021349A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Bispecific antibody constructs binding dll3 and cd3
WO2017147368A1 (en) * 2016-02-24 2017-08-31 Oncomed Pharmaceuticals, Inc. Redirecting immune responses
WO2018057669A1 (en) * 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2844519A1 (fr) * 2002-09-17 2004-03-19 Bio Merieux Proteine recombinante chimerique et diagnostic in vitro
WO2007080597A2 (en) 2006-01-16 2007-07-19 Compugen Ltd. Polynucleotide and polypeptide sequences and methods for diagnosis
US20120042416A1 (en) * 2009-08-24 2012-02-16 Fraunhofer-Gesellschaft zur Forderung der angewandten e.V. Antibody fusion-mediated plant resistance against Oomycota
JP2013507378A (ja) * 2009-10-09 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
CN103003697A (zh) * 2010-05-17 2013-03-27 得克萨斯系统大学董事会 来自动物的单克隆抗体的快速分离
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
BR112015019909A2 (pt) 2013-02-22 2017-08-29 Abbvie Stemcentrx Llc Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
PE20160209A1 (es) * 2013-08-28 2016-05-09 Stemcentrx Inc Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
MA41645A (fr) 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
JP2019516705A (ja) 2016-05-20 2019-06-20 アッヴィ・ステムセントルクス・エル・エル・シー 神経内分泌移行のリスクのある腫瘍を治療するための抗ｄｌｌ３薬物コンジュゲート
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US20190225685A1 (en) 2018-01-24 2019-07-25 Abbvie Stemcentrx Llc Anti-dll3 antibody drug conjugates and methods of use
US20220025037A1 (en) 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
EP3864045A2 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150003169A (ko) * 2012-02-24 2015-01-08 스템 센트알엑스 인코포레이티드 Ｄｌｌ3 조절물질들 및 사용 방법
WO2017021349A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Bispecific antibody constructs binding dll3 and cd3
WO2017147368A1 (en) * 2016-02-24 2017-08-31 Oncomed Pharmaceuticals, Inc. Redirecting immune responses
WO2018057669A1 (en) * 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use

Also Published As

Publication number Publication date
CN118146372A (zh) 2024-06-07
NZ768753A (en) 2025-03-28
KR102922314B1 (ko) 2026-02-04
EP3790586A4 (en) 2022-01-19
AU2019267349A1 (en) 2020-10-29
US20210047399A1 (en) 2021-02-18
BR112020021280A2 (pt) 2021-01-26
EP3790586A1 (en) 2021-03-17
US12325745B2 (en) 2025-06-10
JP2021528047A (ja) 2021-10-21
KR20210008367A (ko) 2021-01-21
SG11202009772PA (en) 2020-11-27
WO2019217145A1 (en) 2019-11-14
CA3097193A1 (en) 2019-11-14
AU2019267349B2 (en) 2025-06-05
ZA202006318B (en) 2025-05-28
IL278466A (https=) 2021-03-01
CN112584860A (zh) 2021-03-30
US20240383979A1 (en) 2024-11-21
US12037391B2 (en) 2024-07-16
CN112584860B (zh) 2024-04-05
JP7455388B2 (ja) 2024-03-26
US20250257127A1 (en) 2025-08-14
MX2020011914A (es) 2021-01-29
WO2019217145A8 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL274152B (en) Anti-galectin-9 antibodies and their uses
IL271477A (en) Anti-cd166 antibodies and their uses
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL269134A (en) Antibodies against PAR2 and their use
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL278466B1 (en) Anti-dll3 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en) Anti-npr1 antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL272476A (en) Anti-Apelin antibodies and their uses
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en) Anti-il-27 antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
IL283890A (en) Anti-periostin antibodies and their uses